Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab

已完结 10 由达姆发布于 2026/9/3 9:43:35

DOI:10.1097/hep.0000000000001444
作者：Heechul Nam, Dong Yun Kim, Do Young Kim, Ji Hoon Kim, Chang Wook Kim, Jaejun Lee, Keungmo Yang, Ji Won Han, Pil Soo Sung, Seung Kew Yoon, Hee Sun Cho, Hyun Yang, Si Hyun Bae, Soon Kyu Lee, Jung Hyun K
文献类型：期刊论文
补充材料：只需要正文

Wolters Kluwer Ovid

Abstract：Background Aims: Atezolizumab plus bevacizumab (AB) has become the standard first-line treatment for advanced hepatocellular carcinoma (HCC). However, identifying reliable prognostic biomar

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:MDPIMicroporous Formation Mechanism of Biaxial Stretching PA6/PP Membranes with High Porosity and Uniform Pore Size Distribution